Ross C. Larue
Immunology and Microbiology · The Ohio State University
Publications
49
Citations
2,107
Est. group size
~2
Recurring co-author estimate
Active years
26
Publishing since 2001
Ross C. Larue studies how retroviruses like HIV integrate their genetic material into host cells, using this knowledge to develop antiviral drugs and gene therapy tools. His work includes designing inhibitors that block viral integration machinery and engineering modified retroviral integrases to insert therapeutic genes at specific genome locations, such as for treating cystic fibrosis. He also investigates related topics like drug toxicity mechanisms and host cell factors that support or resist viral infection.
Publication output has fluctuated over the past decade, peaking around 2021 with a subsequent slowdown, though a small resurgence appears in the most recent years (2024-2026).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Retroviral intasome architecture shapes the dynamics of target DNA search and integration
PLoS Pathogens · 2026
- Functional SLC29A3/ENT3 drives autophagic clearance of intracellular viral particles
SSRN Electronic Journal · 2026
- Functional SLC29A3/ENT3 drives autophagic clearance of intracellular viral particles
Virus Research · 2026
- 281 TALE-guided retroviral integration as a strategy for site-specific CFTR exon delivery
Journal of Cystic Fibrosis · 2025
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport
Pharmaceutics · 2024
- 298 Designer retroviral integrase: a novel strategy for CFTR exon delivery
Journal of Cystic Fibrosis · 2024
- BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Molecules · 2023
- Identification and Optimization of a Novel HIV-1 Integrase Inhibitor
ACS Omega · 2022
- Conformation of HIV-1 Envelope Governs Rhesus CD4 Usage and Simian-Human Immunodeficiency Virus Replication
mBio · 2022
- Retroviral Vectors for Gene Therapy of Monogenic Diseases
2022
- Human immunodeficiency virus integration complexes are active following ordered addition of wild type integrase, viral DNA, and LEDGF/p75
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- Sec24C is an HIV-1 host dependency factor crucial for virus replication
Nature Microbiology · 2021
- Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Frontiers in Molecular Biosciences · 2021
- The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains
Journal of Biological Chemistry · 2021
- Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia
ACS Pharmacology & Translational Science · 2021
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Journal of Biological Chemistry×2
- Journal of Cystic Fibrosis×2
- Cell×1
- Bioconjugate Chemistry×1
- Kristine E. Yoder
Immunology and Microbiology · The Ohio State University
- Ekaterina Knyazhanskaya
Immunology and Microbiology · Indiana University
- Mamuka Kvaratskhelia
Immunology and Microbiology · The Ohio State University
- Amit Sharma
Immunology and Microbiology · The Ohio State University
- Ajay K. Ghosh
Immunology and Microbiology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile